{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38","upperLimit":"68","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Complete Response Rate as defined by the 2006 International Working Group (IWG) criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants who received at least one dose at level 3: 100 mg/kg LBW APR-246 + 75 mg Azacitidine","id":"OG000","title":"Phase 2: Participants in Dose Level 3/MTD"}],"paramType":"NUMBER","populationDescription":"45 participants were evaluable for response","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Phase 2: Complete Response (CR) Rate","type":"PRIMARY","unitOfMeasure":"percentage of patients"}